Know Cancer

forgot password

Maintenance Therapy With Brentuximab Vedotin (SGN-35) After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma and CD30+ Hematologic Malignancies

Phase 1/Phase 2
12 Years
75 Years
Open (Enrolling)
Hematopoietic/Lymphoid Cancer

Thank you

Trial Information

Maintenance Therapy With Brentuximab Vedotin (SGN-35) After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma and CD30+ Hematologic Malignancies


I. To determine the incidence of durable donor hematopoietic engraftment (defined by donor
T-cell chimerism > 50% at day +84 after hematopoietic cell transplantation [HCT]) after
allogeneic HCT and post-transplant brentuximab vedotin.


I. Rates of complete and partial response; incidence of acute graft-versus-host disease
(GVHD) grades II-IV and chronic GVHD; overall and progression-free survival; rates of
serious adverse events associated with brentuximab vedotin.


Patients receive brentuximab vedotin intravenously (IV) on day 1. Treatment repeats every 21
days for up to 16 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for up to 5 years.

Inclusion Criteria:

- Patients must have a cluster of differentiation (CD)30+ malignancy, with CD30
positivity demonstrated either at time of original diagnosis or at any subsequent
time point

- Patients must have undergone allogeneic HCT from a related or unrelated donor;
acceptable donors include:

- Related donors: genotypically or phenotypically identical by serological typing
for human leukocyte antigen (HLA)-A, -B, -C, and at the allele level for -DRB1
and -DQB1

- Unrelated donors: Fred Hutchinson Cancer Research Center (FHCRC) matching
allowed will be grade 1.0 to 2.1: matched for HLA-A, -B, -C, -DRB1 and -DQB1 by
high-resolution typing

- For all donors, a single allele disparity will be allowed for HLA-A, -B, or -C
as defined by high-resolution typing

- Patients with HLA-haploidentical donors are not eligible

- Patients must have documented post-transplant donor CD3+ chimerism of > 50% in sorted
peripheral-blood CD3+ cells

- Patients must be at least 28 days out from allogeneic HCT at the time of enrollment;
in general, patients should be no more than 60 days out from allogeneic HCT at time
of enrollment; however, patients more than 60 days out from allogeneic HCT may be
considered for enrollment in discussion with the protocol investigators (Drs. Rezvani
and/or Maloney)

- Patients must be enrolled on an FHCRC non-myeloablative allogeneic transplant
protocol (not standard treatment plan); for eligibility purposes, "non-myeloablative"
is defined here as conditioning therapy consisting of =< 4 Gy total body irradiation,
with or without fludarabine

- Patients with prior exposure to brentuximab vedotin are eligible for enrollment on
this trial, regardless of previous disease response

- Women of childbearing age and men with female partners of childbearing age must be
willing and able to use an effective method of contraception during the study and for
at least 30 days after the last study dose of brentuximab vedotin

- Patients must be able to give informed consent

Exclusion Criteria:

- Patients who are seropositive for human immunodeficiency virus (HIV)

- Women who are pregnant or breast-feeding

- Patients with moderate to severe peripheral neuropathy (grade 2 or higher); patients
with a history of moderate/severe peripheral neuropathy may be enrolled if their
neuropathy improves to =< grade 1 at the time of enrollment

- Patients with significant hepatic dysfunction, as manifested by a total serum
bilirubin > 4.0 g/dL; or clinical evidence of decompensated hepatic failure; or
clinical evidence of decompensated portal hypertension

- Patients with an absolute neutrophil count of < 1,000 cells/mm^3

- Patients with Eastern Cooperative Oncology Group (ECOG) performance status of > 2

- Patients with a serum creatinine > 3.0 mg/dL

- Patients with known hypersensitivity to brentuximab vedotin or any excipient
contained in the drug formulation

- Patients currently receiving treatment with other systemic anti-neoplastic or
investigational agents targeting their CD30+ hematologic malignancy

- Patients with active and uncontrolled infection not responding to appropriate
treatment should be discussed with the study investigators (Drs. Rezvani or Maloney)
before enrollment

- Patients who have received donor lymphocyte infusion for low donor chimerism or
pending graft rejection are not eligible

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Incidence of durable hematopoietic engraftment defined as the achievement of > 50% donor CD3+ cell chimerism

Outcome Description:

Evaluated according to the allogeneic transplant protocol on which patients are co-enrolled, or according to institutional standard practice if no monitoring scheme is specified in the transplant protocol.

Outcome Time Frame:

At day 84 after HCT

Safety Issue:


Principal Investigator

Andrew Rezvani

Investigator Role:

Principal Investigator

Investigator Affiliation:

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium


United States: Food and Drug Administration

Study ID:




Start Date:

June 2013

Completion Date:

Related Keywords:

  • Hematopoietic/Lymphoid Cancer
  • Hematologic Neoplasms



Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumSeattle, Washington  98109